Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.35 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.35 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31283794 | 1.00 | RECQL (0.35) | RECQLLOXLOXL3LOXL2SMARCA2 | |
| SCHEMBL27463527 | 0.79 | NOS3 (0.52) | KDM4CS1PR1S1PR3SIGMAR1NOS3 | |
| SCHEMBL27334465 | 0.76 | RECQL (0.33) | RECQLLOXLOXL3LOXL2S1PR1 | |
| SCHEMBL20264735 | 0.75 | HDAC6 (0.40) | KDM4C | |
| SCHEMBL17594694 | 0.73 | KDM4E (0.46) | KDM4CWDR5 | |
| SCHEMBL25322547 | 0.73 | TRPA1 (0.40) | TRPA1SIGMAR1 | |
| SCHEMBL28165728 | 0.72 | KDM4C (0.38) | KDM4CTRPA1SIGMAR1 | |
| SCHEMBL31275701 | 0.72 | RECQL (0.38) | RECQLLOXLOXL3LOXL2SMARCA2 | |
| SCHEMBL15390633 | 0.72 | RECQL (0.42) | RECQLLOXLOXL3LOXL2SMARCA2 | |
| SCHEMBL29272414 | 0.71 | RECQL (0.35) | RECQLLOXLOXL3LOXL2SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547657-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240116928-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024006929-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006929-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-107074828-B | Compounds and compositions as RAF kinase inhibitors | 诺华股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-3191478-B1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| EP-3191478-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | Novartis AG (CH) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038582-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RECQL 1468/4885LOX 2028/4885LOXL3 2757/4885 |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | BRAF, RAF1, ARAF | RECQL 1468/4885LOX 2028/4885LOXL3 2757/4885 |
| US-20240116928-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | RECQL 2126/4885LOX 1400/4885LOXL3 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.